ACTELION's takeover by Johnson & Johnson

There is no translation available.

Do you own ACTELION ?

I remember the stock was traded at CHF 30 in the late-nineties, before split ! It was at that time I began to follow the company.

After twenty years, the company has decided today to accept the takeover price per share of CHF 280, from Johnson & Johnson equivalent to a $ 30 billion transaction value.

Built on one drug sales (Pulmonary Arterial Hypertension), the company expanded its turnover through the search and development of innovative drugs for diseases with significant unmet medical needs.

This is a great story thanks to Mrs and Mr Clozel with a happy end for shareholders.

Now, what can we do with cash ?

Please meet one of our Partners to be informed of the latest investment opportunities. 

 

Click on iThis email address is being protected from spambots. You need JavaScript enabled to view it.


Image
We approach each problem with three essential elements: strategic thinking, creative solutions, proven results.
Copyright © 2016 - 2025 by Swiss Profilinvest. All Rights Reserved. Switzerland. Les cookies assurent le bon fonctionnement de notre site Internet. En utilisant ce dernier, vous acceptez leur utilisation. Les cookies ne sont pas utilisés à des fins publicitaires et leurs utilisations sont protégées par la Loi suisse sur la protection des données personnelles. Swiss ProfilInvest est membre de NODE 1922 www.node1922.ch

Designed by OkidocWeb-DevelopmentGraphic-DesignApplications-SoftwareServices

Social Icon

© 2019 JoomShaper, All Right Reserved